Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Ultragenyx Pharmaceutical (RARE) Leases (2019 - 2023)

Ultragenyx Pharmaceutical (RARE) has disclosed Leases for 5 consecutive years, with $26.4 million as the latest value for Q3 2023.

  • Quarterly Leases fell 8.08% to $26.4 million in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $26.4 million through Sep 2023, down 8.08% year-over-year, with the annual reading at $26.0 million for FY2022, 25.69% down from the prior year.
  • Leases for Q3 2023 was $26.4 million at Ultragenyx Pharmaceutical, up from $19.2 million in the prior quarter.
  • The five-year high for Leases was $40.5 million in Q4 2020, with the low at $19.2 million in Q2 2023.
  • Average Leases over 5 years is $31.6 million, with a median of $32.2 million recorded in 2019.
  • The sharpest move saw Leases soared 55.61% in 2020, then crashed 38.48% in 2023.
  • Over 5 years, Leases stood at $30.3 million in 2019, then soared by 33.62% to $40.5 million in 2020, then decreased by 13.79% to $34.9 million in 2021, then fell by 25.69% to $26.0 million in 2022, then increased by 1.8% to $26.4 million in 2023.
  • According to Business Quant data, Leases over the past three periods came in at $26.4 million, $19.2 million, and $22.9 million for Q3 2023, Q2 2023, and Q1 2023 respectively.